Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CANinform | Other Identifier | Aspa Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study uses medical records that allow retrospective data extraction of critical milestone and motor function data. In addition, prospective assessments collect data relevant to the natural history of Canavan disease in children.
The CANinform natural history study is the first multinational effort to rigorously gather both retrospective and prospective data from this patient population. Data collection includes extraction of retrospective data from medical records of living and deceased patients, and collection of prospective, longitudinal data from living patients and their parent(s)/caregiver(s). Motor function assessments are performed remotely in the home via video or in the clinic by qualified study team members. Families will be invited to attend clinic visits and/or will be followed remotely by the clinical site for approximately 3 years.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1 (Age < 18 Months) |
| ||
| Cohort 2 (Age ≥ 18 Months - 3 Years) |
| ||
| Cohort 3 (Age > 3 - 5 Years) |
| ||
| Cohort 4 (Age > 5 Years) |
| ||
| Cohort 5 (Deceased) | • The patient's medical history records will be reviewed. In addition, a parent interview will be performed. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| To characterize the natural history of Canavan disease | To enhance the understanding of the natural history of Canavan disease through retrospective data collection from patient medical records and prospective data collection from living patients, including: phenotypic characteristics and variability, genotype characteristics and variability, and disease progression and natural history. | approximately 3 years |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
1. Patient does not meet the Inclusion Criteria.
Not provided
Not provided
Not provided
Not provided
Living and deceased patients with Canavan disease
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UCSF Benioff Children's Hospital Oakland | Oakland | California | 94609 | United States | ||
| Massachusetts General Hospital |
Not provided
| Label | URL |
|---|---|
| Aspa Therapeutics Company Website | View source |
| CANinform Study Website | View source |
Not provided
Data will be made available for researchers using a defined process.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017825 | Canavan Disease |
| D035583 | Rare Diseases |
| D056784 | Leukoencephalopathies |
| ID | Term |
|---|---|
| D020279 | Hereditary Central Nervous System Demyelinating Diseases |
| D020739 | Brain Diseases, Metabolic, Inborn |
| D001928 | Brain Diseases, Metabolic |
| D001927 | Brain Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Hematology, blood chemistry, urinalysis, genetic mutation confirmation, antibody testing
| Boston |
| Massachusetts |
| 02114 |
| United States |
| University Medical Center Hamburg-Eppendorf | Hamburg | 20246 | Germany |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
| D020271 | Heredodegenerative Disorders, Nervous System |
| D019636 | Neurodegenerative Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D008661 | Metabolism, Inborn Errors |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |